RYBELSUS® indication

The world's first and only oral GLP-1 RA

RYBELSUS® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise:

• As monotherapy when metformin is considered inappropriate due to intolerance or contraindications.

• In combination with other medicinal products for the treatment of diabetes.

For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, please refer to the full SmPC1

Click here↗ for RYBELSUS® prescribing information

GLP-1 RA=glucagon-like peptide-1 receptor agonist


1. Novo Nordisk Limited; GB & NI RYBELSUS® SmPCs.

UK22RYB00380 | February 2023

Adverse events and precautions

Read more about RYBELSUS® adverse events and select precautions for use

Special populations

Learn about RYBELSUS® dosing for special populations

Need more information?

Learn more about RYBELSUS® from one of our promotional Novo Nordisk representatives